BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria ...Middle East

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA)...

Read More Details
Finally We wish PressBee provided you with enough information of ( BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria )

Also on site :

• Kremlin reveals how Putin will take part in BRICS summit
• Author Gets Honest About LeBron James, Michael Jordan's Legacy in New Book
• Faith leaders challenge Texas law requiring Ten Commandments in classrooms